Corbus Pharmaceuticals Holdings, Inc.

As of June 30, 2026, Corbus Pharmaceuticals Holdings Inc carries a market capitalization of 143.95M, placing it among publicly traded companies globally. Its enterprise value stands at 44.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Corbus Pharmaceuticals Holdings Inc's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Corbus Pharmaceuticals Holdings Inc has 17.74M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Corbus Pharmaceuticals Holdings Inc maintains a current ratio of 5.71, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Corbus Pharmaceuticals Holdings Inc posted a negative return on equity (ROE) of -95.58, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -80.85, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 34.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Corbus Pharmaceuticals Holdings Inc's stock has declined approximately 76.31% over the past 52 weeks. The 50-day moving average sits at 6.90, while the 200-day moving average is 7.56.

Over the twelve months ended June 30, 2026, Corbus Pharmaceuticals Holdings Inc generated - - in revenue and converted that into -89.20M in net income, yielding earnings per share of -5.33. EBITDA reached -93.38M, while operating income came in at -93.55M.

As of June 30, 2026, Corbus Pharmaceuticals Holdings Inc holds 103.23M in cash and equivalents against 3.73M in total debt, resulting in a net debt position of -20.46M. Total book value stands at 89.49M, with working capital of 88.64M providing operational flexibility.

Corbus Pharmaceuticals Holdings Inc produced -75.86M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10,503.60 in capital expenditures, free cash flow totaled -75.87M - equivalent to -4.54 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -55.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

Corbus Pharmaceuticals Holdings Inc's most recent stock split took place on February 14, 2023 with a 30:1 split ratio.

As of June 30, 2026, Corbus Pharmaceuticals Holdings Inc has an Altman Z-Score of -4.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.